## Contents

### Part I  Biology of Renal Cell Carcinoma

1. **The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies** .................................................. 3  
   Laura S. Schmidt, Ramaprasad Srinivasan, and W. Marston Linehan

2. **Molecular Biology of Clear Cell Renal Carcinoma** ................. 27  
   William G. Kaelin Jr.

3. **HIF Biology in RCC: Implications for Signaling, Disease Progression, and Treatment** .................................................. 49  
   W. Kimryn Rathmell

4. **Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC** ................................................................. 69  
   Brittany Bahamon and Sabina Signoretti

5. **Molecular Characterization of Renal Cell Carcinoma** ............... 91  
   Bin Tean Teh, Leslie J. Farber, and Kyle Furge

### Part II  Current and Future Molecular Targets for RCC

6. **Targeting the VEGF Pathway in Renal Cell Carcinoma** ............. 115  
   Cristina Suarez and Brian I. Rini

7. **Angiopoietins and Other Non-VEGF Antiangiogenic Targets in Advanced Renal Cell Carcinoma** ................................. 135  
   C. Lance Cowey and Thomas E. Hutson

8. **Research Translation and Personalized Medicine** .................... 161  
   James Brugarolas
9 Epigenetic Targeting and Histone Deacetylase Inhibition in RCC ................................................................. 193
Swathi Ramakrishnan and Roberto Pili

10 C-MET as a Novel Target for the Treatment of Renal Cell Carcinoma ......................................................... 213
Hema Vankayala, Patricia LoRusso, and Ulka Vaishampayan

11 Characterizing and Modulating the Tumor Microenvironment in Renal Cell Carcinoma: Potential Therapeutic Strategies .............................................................. 239
Sumanta Kumar Pal, Karen Reckamp, Hua Yu, and Robert A. Figlin

12 Carbonic Anhydrase IX: Its Role as a Biomarker, Diagnostic, and Therapeutic Target in Renal Cell Carcinoma ................................................................. 253
E. Oosterwijk, A.B. Stillebroer, and P.F.A. Mulders

13 Presurgical Therapy for Renal Cell Carcinoma and Implications for Window-of-Opportunity Trials .................. 271
Hyung L. Kim, Edwin M. Posadas, and Robert A. Figlin

14 Mechanisms of Resistance to VEGF-Directed Therapy and Implications for Future Trial Design .................... 283
James W. Mier

15 Vaccine-Based Immunotherapy and Targeting the Tumor Microenvironment in Renal Cell Carcinoma .......... 305
Johannes Vieweg

Index .................................................................................................................................................. 323
Renal Cell Carcinoma
Translational Biology, Personalized Medicine, and Novel Therapeutic Targets
Figlin, R.A.; Rathmell, W.K.; Bloom, J. (Eds.)
2012, XII, 328 p., Hardcover
ISBN: 978-1-4614-2399-7